Atlas Trials

Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Clinical trial NCT01348919 · COMPLETED

Trial details

NCT number
NCT01348919
Sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma
Start date
2011-08-03
Primary completion
2013-03-14
Enrollment
11

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.